Yearly Archives: 2022
Senate HELP Committee Advances PREVENTS Pandemic Act
The Senate HELP Committee on Tuesday voted 20-2 to advance legislation, the PREVENTS Pandemic Act.
Co-Diagnostics, Inc. Announces Authorization of $30 Million Share Repurchase Program
Co-Diagnostics announced that its Board of Directors has authorized a share repurchase program that would allow the Company to repurchase up to $30 million of CODX common stock.
Tillis, Coons, Cotton, Hirono, and Scott Introduce Bipartisan Bill to Prevent the Chinese Communist Party from Stealing American Intellectual Property
Legislation would combat corrupt Chinese Courts from issuing “anti-suit injunctions” that prevent companies from challenging patent infringement from Chinese companies in American courts.
2022 Wilson Sonsini Entrepreneur and Investor Life Sciences Summit is a Raging Success
The 2022 Wilson Sonsini Entrepreneur and Investor Life Sciences Summit presented by BioUtah, BioHive and the PIVOT Center attracted a record setting 300+ registrants along with an impressive line-up of distinguished speakers, national and local investors and numerous Utah life sciences startups. Now in its 7th year, the Summit (our first in person since COVID-19) […]
Xenter Selects New Headquarters in Draper
Xenter has leased 30,000 square feet to accommodate explosive growth in the new Irvine Office Park in Draper, Utah.
Renalytix Launches myIntelX, Providing National Physician Access to KidneyIntelX Testing Platform
myIntelX will be launching in conjunction with KidneyIntelX going live at Atrium Health, and will expand testing services across all Renalytix healthcare provider partners
IONIQ Sciences announces IP acquisition and License buyout
IONIQ Sciences announced that it has acquired from OT Acceptance, LLC certain intellectual property formerly licensed to the Company by OT Acceptance.
Metastatic Tumor Treatment with Novel GPX Embolic Device
Innovative Embolic Device by Fluidx Medical Used Successfully in a Variety of Complex Cancer Cases
Known Medicine Partners with Duke University to Predict Lung Cancer Response to Drug Treatments
Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer
Halia Therapeutics New Leadership Team
Halia Therapeutics New Leadership Team
BD Names William ‘Bill’ Brown to Board of Directors
BD Names William ‘Bill’ Brown to Board of Directors
DiscGenics Announces Presentation of Positive Interim Clinical Data from Phase 1/2 Study of Cell Therapy for Degenerative Disc Disease
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection; improvements were sustained at the one-year interim readout with additional data to follow at 18 and 24 months.
